ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Jun 09, 2021 11:31 JST
Source:
Eisai
Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021)
TOKYO, Jun 09, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.
Major poster presentations include the results of a study evaluating next-dose transition from zolpidem to lemborexant for insomnia treatment (Poster Numbers: #335 and #337).
Eisai considers neurology a therapeutic area of focus. Eisai strives to create innovative products in therapeutic areas with high unmet medical needs as soon as possible, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with neurological diseases and their families.
For more information, visit
https://www.eisai.com/news/2021/news202143.html
.
Source: Eisai
Sectors: BioTech
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Fujitsu Kozuchi AI technologies assist AKOS AI in delivering solutions for EU AI compliance
Apr 18, 2025 17:41 JST
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
Apr 18, 2025 16:52 JST
Hitachi Industrial Equipment Systems Launches Next-Generation Inverter System to Support Stable, Resilient Power Grids
Apr 18, 2025 16:46 JST
MHIEC Receives Order from the Bureau of Sewerage of the Tokyo Metropolitan Government for Rebuilding of Sewage Sludge Incineration Facility
Apr 17, 2025 14:44 JST
Fujitsu collaboration with Supermicro and Nidec to reduce data center energy consumption
Apr 17, 2025 10:32 JST
Fujitsu's Japanese language enhanced LLM Takane offering now available on Nutanix Enterprise AI solution
Apr 16, 2025 11:24 JST
Isuzu and Fujitsu sign partnership agreement to commercialize software defined vehicles
Apr 15, 2025 12:29 JST
MHI Awarded a Study on CO2 Capture Modules for FPSOs
Apr 15, 2025 10:46 JST
Mitsubishi Motors Begins Shipping Xforce HEV Model in Thailand
Apr 11, 2025 15:03 JST
Collaboration to Make Engine-Equipped Vehicles Carbon Neutral Using Synthetic Fuel
Apr 11, 2025 14:03 JST
TGR to Launch Evolved GR Yaris
Apr 11, 2025 13:35 JST
Fujitsu develops employee training platform for Seven-Eleven Japan to accelerate store digitalization
Apr 11, 2025 11:29 JST
Mitsubishi Corporation makes DennoKotsu an equity-method affiliate company, strengthening efforts to address regional transportation challenges
Apr 11, 2025 10:39 JST
JCB Enhances Customer Experience with Expanded Payment Acceptance for App Store and Apple Services in Asia
Apr 11, 2025 10:00 JST
Fujitsu and Headwaters trial on-device generative AI solution to streamline JAL cabin crew workflows
Apr 11, 2025 09:07 JST
Mitsubishi Logisnext Delivers Container Terminal Gate System with Enhanced Functionality to Port of Osaka
Apr 10, 2025 16:23 JST
Mitsubishi Shipbuilding Acquired Approval in Principle (AiP) from Classification Society for the Basic Design of an Onboard Carbon Capture and Storage System
Apr 10, 2025 14:17 JST
Honda NC750X Named Winner in 2025 Red Dot Design Award: Product Design Category, EM1 e: Wins 2025 iF Design Award: Product Design Category
Apr 10, 2025 13:13 JST
Mitsubishi Corporation to Participate in Demonstration Project for New Hydrogen-Based Ironmaking
Apr 09, 2025 18:22 JST
SinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis
Apr 09, 2025 15:49 JST
More Latest Release >>
Related Release
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
4/18/2025 4:52:00 PM JST
Eisai to Divest Rights for Pariet in China to Peak Pharma
4/1/2025 1:15:00 PM JST
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards
3/25/2025 5:28:00 PM JST
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace
3/25/2025 12:21:00 PM JST
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
3/10/2025 8:24:00 PM JST
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
3/5/2025 9:09:00 AM JST
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
3/4/2025 5:22:00 PM JST
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
3/3/2025 3:41:00 PM JST
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
3/3/2025 1:53:00 PM JST
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
2/28/2025 12:31:00 PM JST
More Press release >>